Reduction of HBV and HDV infection in two indigenous peoples of Peruvian Amazon after the vaccination against hepatitis B

César Cabezas, Omar Trujillo, Johanna Balbuena, Manuel Terrazas, Carlos Manrique-de Lara, Luis Marín, Max Carlos Ramírez-Soto

Research output: Contribution to journalArticlepeer-review

Abstract

© 2020, Instituto Nacional de Salud Publica. Objective. To determine the outcome of the vaccination against hepatitis, we determined the prevalence of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections, eight years after introduction of the vaccination. Materials and methods. A cross-sectional study was performed in 2 944 participants of 67 Kandozi and Chapra indigenous peoples in April 2010. Serological screening for hepatitis B surface antigen (HBsAg), antibody anti-HBc IgM and IgG, antibody anti-HBs and anti-HDV were determined by ELISA tests. Results. The prevalence rates of HBsAg, anti-HBc total, anti-HBs ≥10 mlUI/ml and anti-HDV were 2.3, 39.13, 50.95 and 2.11%, respectively. The prevalence rate of HBsAg in children <11 years was 0%. Among carriers of HBsAg, the prevalence rates of HDV and acute HBV infections were 2.11% (all were >14 years) and 11.94%, respectively. HBsAg and anti-HBc total were associated with individuals ≥10 years (p<0.001). Conclusions. These findings show the elimination of HBV carriers in children <11 years, eight years following introduction of the vaccination against HBV.
Original languageAmerican English
Pages (from-to)237-245
Number of pages9
JournalSalud Publica de Mexico
DOIs
StatePublished - 1 Jan 2020

Fingerprint Dive into the research topics of 'Reduction of HBV and HDV infection in two indigenous peoples of Peruvian Amazon after the vaccination against hepatitis B'. Together they form a unique fingerprint.

Cite this